SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rick J. Jansen, Bruce H. Alexander, Kristin E. Anderson, Timothy R. Church, Quantifying lead-time bias in risk factor studies of cancer through simulation, Annals of Epidemiology, 2013, 23, 11, 735

    CrossRef

  2. 2
    Grace Hui-Min Wu, Anssi Auvinen, Liisa Määttänen, Teuvo L.J. Tammela, Ulf-Håkan Stenman, Matti Hakama, Amy Ming-Fang Yen, Hsiu-Hsi Chen, Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening, International Journal of Cancer, 2012, 131, 6
  3. 3
    N. Becker, Epidemiologie des Prostatakarzinoms, Der Radiologe, 2011, 51, 11, 922

    CrossRef

  4. 4
    Nora Pashayan, Paul Pharoah, David E. Neal, Freddie Hamdy, Jenny Donovan, Richard M. Martin, David Greenberg, Stephen W. Duffy, PSA-detected prostate cancer and the potential for dedifferentiation—estimating the proportion capable of progression, International Journal of Cancer, 2011, 128, 6
  5. 5
    C. Börgermann, F. vom Dorp, G. Breuer, S. Kliner, H. Rübben, Früherkennung von Prostatakarzinomen, Der Urologe, 2010, 49, 11, 1351

    CrossRef

  6. 6
    Chris H. Bangma, Ron H. van Schaik, Bert G. Blijenberg, Monique J. Roobol, Hans Lilja, Ulf-Håkan Stenman, On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer, European Journal of Cancer, 2010, 46, 17, 3109

    CrossRef

  7. 7
    C. Hamashima, T. Nakayama, M. Sagawa, H. Saito, T. Sobue, The Japanese Guideline for Prostate Cancer Screening, Japanese Journal of Clinical Oncology, 2009, 39, 6, 339

    CrossRef

  8. 8
    Anne Aupérin, Agnès Laplanche, Catherine Hill, Dépistage du cancer de la prostate dans la population générale: des inconvénients certains, un bénéfice hypothétique, La Presse Médicale, 2007, 36, 7-8, 1045

    CrossRef

  9. 9
    Dawn Stacey, Sophie Hill, Patient-direct and patient-mediated KT interventions,